​

UroGen Pharma (URGN) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

UroGen Pharma Revenue Highlights

Latest Revenue (Y)

$82.71M

Latest Revenue (Q)

$25.20M

Main Segment (Y)

Jelmyto

UroGen Pharma Revenue by Period

UroGen Pharma Revenue by Year

DateRevenueChange
2023-12-31$82.71M28.52%
2022-12-31$64.36M33.96%
2021-12-31$48.04M307.17%
2020-12-31$11.80M65450.00%
2019-12-31$18.00K-98.40%
2018-12-31$1.13M-86.17%
2017-12-31$8.16M-53.46%
2016-12-31$17.53M100.00%
2015-12-31--

UroGen Pharma generated $82.71M in revenue during NA 2023, up 28.52% compared to the previous quarter, and up 7332.71% compared to the same period a year ago.

UroGen Pharma Revenue by Quarter

DateRevenueChange
2024-09-30$25.20M15.36%
2024-06-30$21.85M16.33%
2024-03-31$18.78M-20.18%
2023-12-31$23.53M12.84%
2023-09-30$20.85M-1.36%
2023-06-30$21.14M22.96%
2023-03-31$17.19M-4.97%
2022-12-31$18.09M12.39%
2022-09-30$16.10M-3.05%
2022-06-30$16.60M22.41%
2022-03-31$13.56M-16.14%
2021-12-31$16.17M42.49%
2021-09-30$11.35M-12.90%
2021-06-30$13.03M74.11%
2021-03-31$7.49M-6.04%
2020-12-31$7.97M130.16%
2020-09-30$3.46M830.38%
2020-06-30$372.00K100.00%
2020-03-31-100.00%
2019-12-31-100.00%
2019-09-30--100.00%
2019-06-30$18.00K100.00%
2019-03-31-100.00%
2018-12-31--100.00%
2018-09-30$283.00K-22.25%
2018-06-30$364.00K-24.32%
2018-03-31$481.00K47.09%
2017-12-31$327.00K-95.81%
2017-09-30$7.81M100.00%
2017-06-30--100.00%
2017-03-31$19.00K-99.89%
2016-12-31$17.53M100.00%
2016-09-30-100.00%
2016-06-30--

UroGen Pharma generated $25.20M in revenue during Q3 2024, up 15.36% compared to the previous quarter, and up 119.23% compared to the same period a year ago.

UroGen Pharma Revenue Breakdown

UroGen Pharma Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 23Dec 22Dec 21Dec 18
Jelmyto$82.71M$64.36M$48.04M-
R T Gel---$1.10M

UroGen Pharma's latest annual revenue breakdown by segment (product or service), as of Dec 23: Jelmyto (100.00%).

Quarterly Revenue by Product

Product/ServiceSep 24Mar 24Dec 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21
Jelmyto$25.20M$18.78M$44.38M$21.14M$17.19M$18.09M$16.10M$16.60M$13.56M$16.17M$11.35M

UroGen Pharma's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Jelmyto (100.00%).

UroGen Pharma Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
OVIDOvid Therapeutics$391.69M$173.00K
URGNUroGen Pharma$82.71M$25.20M
IKNAIkena Oncology$9.16M-
KRONKronos Bio$6.29M$2.37M
GBIOGeneration Bio$5.90M$4.09M
PRTCPureTech Health$3.33M$178.57K
INBXInhibrx Biosciences$1.80M-
CCCCC4 Therapeutics--
TARAProtara Therapeutics--
CNTBConnect Biopharma--
ERASErasca--
CELCCelcuity--
VIGLVigil Neuroscience--
ELVNEnliven Therapeutics--
CMPXCompass Therapeutics--
EWTXEdgewise Therapeutics--
SRRKScholar Rock--
PEPGPepGen--
TYRATyra Biosciences--
XLOXilio Therapeutics-$2.36M

URGN Revenue FAQ

What is UroGen Pharma’s yearly revenue?

UroGen Pharma's yearly revenue for 2023 was $82.71M, representing an increase of 28.52% compared to 2022. The company's yearly revenue for 2022 was $64.36M, representing an increase of 33.96% compared to 2021. URGN's yearly revenue for 2021 was $48.04M, representing an increase of 307.17% compared to 2020.

What is UroGen Pharma’s quarterly revenue?

UroGen Pharma's quarterly revenue for Q3 2024 was $25.2M, a 15.36% increase from the previous quarter (Q2 2024), and a 20.87% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $21.85M, a 16.33% increase from the previous quarter (Q1 2024), and a 3.35% increase year-over-year (Q2 2023). URGN's quarterly revenue for Q1 2024 was $18.78M, a -20.18% decrease from the previous quarter (Q4 2023), and a 9.24% increase year-over-year (Q1 2023).

What is UroGen Pharma’s revenue growth rate?

UroGen Pharma's revenue growth rate for the last 3 years (2021-2023) was 72.17%, and for the last 5 years (2019-2023) was 459416.67%.

What are UroGen Pharma’s revenue streams?

UroGen Pharma's revenue streams in c 23 are Jelmyto

What is UroGen Pharma’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of UroGen Pharma was Jelmyto. This segment made a revenue of $82.71M, representing 100.00% of the company's total revenue.